 |
| About Bioline | All Journals | Testimonials | Membership | News |
|
||||||
|
||||||
Indian Journal of Cancer, Vol. 48, No. 3, July-September, 2011, pp. 385 Letter to Editor Tamoxifen-induced hepatotoxicity N Ahbeddou, R Belbaraka, M Fetohi, H Errihani Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco Code Number: cn11109 PMID: 21921356 DOI: 10.4103/0019-509X.84935 Sir, Since 1970s, the tamoxifen is widely prescribed as therapy for estrogen receptor-positive breast cancer. This anti-estrogenic drug has a proven efficacy in prolonging disease-free and overall survival with a good tolerability profile. [1] Safety data of tamoxifen have been well documented and hepatic disorders are not common. We report a very rare case of hepatic severe adverse event related to tamoxifen. A 46-year-old woman, with no previous medical history of hepatic disease, presented a left breast mass. A biopsy revealed a lobular breast carcinoma. She underwent modified mastectomy with axillary lymphadenectomy. Full staging investigations were performed and were negative. Four courses of adjuvant chemotherapy (doxorubicine and cyclophosphamide) and adjuvant radiation were performed. Then hormonal therapy with tamoxifen was started. The patient was not taking other medicines. Four weeks after initiation of treatment, the patient presented jaundice. Physical examination did not revealed hepatomegaly. Neither hepatic metastasis nor main bile duct obstruction was detected by abdominal ultrasound and CT scan. Laboratory tests showed elevated levels of bilirubin, aminotransferase, and alkaline phosphatase consistent with an acute hepatic injury. Serological and immunologic tests were negative. One month after suspension of tamoxifen, bilirubin level was normalized. Keeping the discontinuation, the patient's alkaline phosphatase and serum aminotransferase levels steadily decreased and return to baseline levels in approximately 6 weeks. Rechallenge was not attempted. The patient had oophorectomy and she remained with no evidence of cancer's relapse at 10 months without further hepatic disorders. Tamoxifen is considered as a safe drug. Its most common side events are hot flashes, mood disturbances, vaginal dryness, proliferative effect on the endometrium, and venous thrombosis. [1] Hepatic adverse events are rare; however, the imputability of our patient's hepatic alterations to tamoxifen has been established by the use of criteria of drug-induced liver disorders. [2],[3] Tamoxifen hepatotoxicity is uncommon and has been assessed by case histories and reports from clinical trials. In previous reports, the potentially tamoxifen-induced liver diseases are essentially steatosis and cholestatic syndrome. [1],[4] Severe hepatotoxicity is a rare complication, but can occur at any time of tamoxifen therapy. Many factors could influence patient susceptibility to hepatotoxicity such as concomitant chronic liver diseases, age, nutritional status, and diet. [5] Acknowledgement The authors thanks the patient for his contribution. References
Copyright 2011 - Indian Journal of Cancer |
| |||||||||
